335 related articles for article (PubMed ID: 3122880)
1. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
2. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
3. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.
Kontoghiorghes GJ; Aldouri MA; Sheppard L; Hoffbrand AV
Lancet; 1987 Jun; 1(8545):1294-5. PubMed ID: 2884415
[TBL] [Abstract][Full Text] [Related]
4. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
5. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
[TBL] [Abstract][Full Text] [Related]
6. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
[TBL] [Abstract][Full Text] [Related]
7. Oral deferiprone for iron chelation in people with thalassaemia.
Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
[TBL] [Abstract][Full Text] [Related]
8. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
[TBL] [Abstract][Full Text] [Related]
9. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
[TBL] [Abstract][Full Text] [Related]
10. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
Kontoghiorghes GJ
Indian J Pediatr; 1993; 60(4):485-507. PubMed ID: 8262586
[TBL] [Abstract][Full Text] [Related]
11. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
[TBL] [Abstract][Full Text] [Related]
12. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
14. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
[TBL] [Abstract][Full Text] [Related]
15. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.
Olivieri NF; Templeton DM; Koren G; Chung D; Hermann C; Freedman MH; McClelland RA
Ann N Y Acad Sci; 1990; 612():369-77. PubMed ID: 2291564
[No Abstract] [Full Text] [Related]
18. A risk-benefit assessment of iron-chelation therapy.
Porter JB
Drug Saf; 1997 Dec; 17(6):407-21. PubMed ID: 9429839
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with deferiprone and desferrioxamine.
Wonke B; Wright C; Hoffbrand AV
Br J Haematol; 1998 Nov; 103(2):361-4. PubMed ID: 9827905
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]